Seek prompt medical attention if you experience any of the following: Severe or worsening pain, warmth, or swelling at the injection site, which may suggest infection Signs of an allergic reaction: rash, urticaria, facial swelling, difficulty breathing, or anaphylaxis Persistent or severe abdominal pain, which may indicate pancreatitis Right upper quadrant pain, fever, or jaundice, which may indicate gallbladder disease (e.g., cholelithiasis or cholecystitis) a recognised risk with incretin-class therapies Signs of dehydration from persistent vomiting or diarrhoea: reduced urine output, dizziness, or feeling faint on standing this may indicate acute kidney injury and requires urgent assessment Rapid heart rate, dizziness, or fainting Symptoms of hypoglycaemia (particularly if taking concomitant insulin or sulphonylureas): shakiness, sweating, confusion, or palpitations Any new or worsening visual symptoms, particularly if you have diabetes, as rapid improvement in blood glucose control has been associated with worsening of diabetic retinopathy in some patients [7] [8] In the UK, patients experiencing a severe or life-threatening reaction should call 999

It is determined by the purpose of the research and the design
At 250mcg per dose, that's 20 doses
Among patients without type 2 diabetes, GLP-1 use was associated with a 34% lower fracture risk for those with osteopenia and 38% lower risk for those with osteoporosis
Risk of malignant neoplasia with glucagon-like peptide1 receptor agonist treatment in patients with type 2 diabetes: a metaanalysis
The goal is to achieve even greater weight loss compared to GLP-1 monotherapy